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Abstract
Background: Researchers in clinical trials in rheumatoid arthritis (RA) and osteoarthritis (OA) often measure pain levels
with a visual analogue scale (VAS). Of interest to clinical practice and future clinical trial design are associations of
change from baseline (CFB) between time points with predictive ability of earlier response for long-term treatment
benefit. We assessed the association and predictive ability of CFB in VAS pain between 2, 6 and 12 weeks in
randomised controlled trials (RCTs) of non-steroidal anti-inflammatory drugs (NSAIDs).
Methods: Aggregated VAS pain data at baseline and CFB at 2, 6 and 12 weeks were collected from a systematic
literature review of 176 RCTs in OA and RA. The predictive ability of earlier assessments for longer-term pain reduction
was estimated using correlation and regression analyses. Analysis was performed using the R software package for
statistical programming, version 3.1.1.
Results: Appropriate data were available from 50 RCTs (22,854 patients). Correlations between time points were high
(weighted correlation coefficients between 2 and 6 weeks, 0.84; between 2 and 12 weeks, 0.79; and between 6 and
12 weeks, 0.96). CFB at 6 weeks was highly predictive and close to CFB at 12 weeks (regression coefficient 0.9, 95 %
confidence interval 0.9–1.0). CFB at 2 weeks was significantly associated with CFB at 12 (0.8, 0.7–0.8) and 6 weeks
(0.9, 0.8–1.0).
Conclusions: The results showed that early analgesic response measured by VAS for pain beyond 2 weeks of
treatment with a particular NSAID is likely to be predictive of response at 12 weeks. Failure to achieve desired pain
relief in OA and RA after 2 weeks should trigger reassessment of dosage and/or analgesic.
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Background
Osteoarthritis (OA) and rheumatoid arthritis (RA) are
the most common arthritic conditions in adults [1].
They lead to joint degeneration and chronic pain [2, 3].
Their prevalence is increasing with an aging population
[4], and pain management is a global public health
priority [5, 6]. Worldwide, OA is the 11th most common
condition causing long-term disability [7].
Non-steroidal anti-inflammatory drugs (NSAIDs), both
traditional and cyclooxygenase 2 inhibitors (COXIBs),
are commonly prescribed to relieve pain and inflamma-
tion [2, 3] and are the cornerstones for treating pain in
arthritis [8, 9]. Knowledge of their effectiveness derives
from randomised trials and meta-analyses of randomised
trials. In these trials, pain is typically measured using a
visual analogue scale (VAS) or a categorical scale. While
clearly not the only outcome of interest, pain is an
important efficacy outcome in OA and RA trials and
perhaps the one most important to patients [10–13].
Recent clinical trials have follow-up periods of
12 weeks, which has become a regulatory requirement
for registration of symptom-modifying drugs in OA [14].
Change from baseline (CFB) in pain levels is often
assessed at multiple time points to evaluate efficacy,
though analyses at the level of the individual patient have
also become available in some cases [15]. In analyses of ef-
ficacy, researchers have tended to express their results as
those at 12 weeks, and they often comment briefly, if at
all, on the dynamics of changes over time. Particularly
missing from the literature is evidence relating later, and
presumably ongoing, benefit to early benefit. Limited pre-
vious work on OA has indicated that early response is pre-
dictive of later response [16], and there are supportive
findings in fibromyalgia and acute pain [17, 18].
While many clinicians may recognise the link between
early and late pain response and non-response in their
everyday practice, this tends not to be reflected in guid-
ance. For example, if early non-response predicted that
there would be no later response, guidance might well
suggest early switching of therapy in the face of non-
response after 2, 4 or 6 weeks. This does not happen,
and, as a consequence, perhaps pain is frequently poorly
treated: over half of patients still had moderate or severe
pain despite being on treatment [19].
This study builds on a large, recent systematic review
and network meta-analysis of traditional NSAIDs and
COXIBs in patients with OA or RA in which researchers
examined relative benefits and risks [20]. The data
collected in that systematic review were derived from
146,524 patients in 176 studies and offered a unique
opportunity for additional analyses.
In the present study, we therefore set out to assess the
association and predictive ability of CFB in VAS pain
scores between the time points of 2, 6 and 12 weeks in
randomised controlled trials (RCTs) including traditional
NSAIDs, COXIBs and placebo. The predictive ability of
earlier pain measurements for long-term treatment
benefit is of interest to clinical practice and future
clinical trial design, and would add substantially to the
currently available literature in arthritis.
Methods
The evidence base for this analysis was obtained from a
recently published systematic literature review that in-
cluded 176 RCTs with a total of 146,524 patients with OA
and RA [20]. This review was conducted in June 2013
using MEDLINE, Embase and the Cochrane Library to
identify RCTs comparing diclofenac, ibuprofen, naproxen,
celecoxib or etoricoxib with each other or with placebo.
Efficacy data were collected, including pain relief mea-
sured with the VAS or the Western Ontario McMaster
Universities Arthritis Index VAS at three time points: 2, 6
and 12 weeks of treatment.
To assess the association between mean CFB in VAS
pain scores, a linear regression model was fitted for all
the possible pairs of subsequent measurements, with the
later time point as an outcome and the earlier time point
as the predictor. Thus, three models were fitted to the
respective available data: model 1, predicting mean CFB
at 6 weeks based on mean CFB at 2 weeks; model 2, pre-
dicting mean CFB at 12 weeks based on mean CFB at
2 weeks; and model 3, predicting mean CFB at 12 weeks
based on mean CFB at 6 weeks.
Each treatment arm was treated as a data point, while
random intercept models were fitted to account for clus-
tering within studies.
As the number of patients analysed in each of the in-
cluded studies varied considerably, the weight of each
data point should be taken into consideration propor-
tionally. Thus, two weighting options were tested for
these models: (1) weighting by the sample size used at
the later measurement and (2) weighting by the preci-
sion of the later measurement, implying the outcome
variable of each model. The Akaike information criterion
(AIC) was used for selecting the model option that best
fit the data. Models with a smaller AIC are better sup-
ported by the data. R software for statistical program-
ming [21], version 3.1.1, was used for the analysis.
Correlation coefficients (Pearson’s r) are presented
with the weighting method used. This is a measure of
the linear correlation between two variables, x and y,
giving a value between +1 and −1 inclusive, where 1 is
total positive correlation, 0 is no correlation and −1 is
total negative correlation.
Results
The evidence base used for our analysis consisted of 50
RCTs (from the 176 identified RCTs in the original
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literature review [20]) in which CFB was reported for at
least two of the time points (2, 6 or 12 weeks) of inter-
est. All these RCTs were included in the regression mod-
elling, as they reported both the sample size and the
standard error of the estimates for at least one of the
time points of interest and thus weighted regression
models could be estimated. The individual study results
used for our analyses are presented in Additional file
1. Details on study design and patient characteristics
of all included studies are provided in a previously
published article [20] and in Additional files 2 and 3,
respectively.
Overall, 33 RCTs (76 arms, 14,919 patients) reported
VAS pain scores at 2 and 6 weeks (model 1), 21 RCTs
(54 arms, 12,618 patients) at 2 and 12 weeks (model 2)
and 26 RCTs (63 arms, 14,643 patients) at 6 and
12 weeks (model 3). Descriptive statistics on CFB in
VAS pain scores at weeks 2, 6 and 12 are shown in Table 1.
These data indicate that the mean and median CFB in
VAS pain scores had only limited variation over time.
Sample size weighted correlation coefficients between
the three time points are presented in Table 2. Pearson’s
r values are 0.84 between 2 and 6 weeks, 0.79 between 2
and 12 weeks, and 0.96 between 6 and 12 weeks. This
indicates a very strong positive association between out-
comes at the evaluated time points, and that for most
patients early and later response or non-response will be
much the same, with few experiencing a different late re-
sponse compared with the early response. Clinical effect
(decrease in VAS pain score) observed at the earlier time
points (i.e., 2 or 6 weeks) of treatment is associated with
the effect (decrease in VAS pain score) at the later time
points (i.e., 6 or 12 weeks). Thus, clinical effect (decrease
in VAS pain score) observed at the earlier time points
(i.e., 2 or 6 weeks) of treatment is predictive of the effect
at the later time points (i.e., 6 or 12 weeks).
The (average) intercept and slope, together with the
95 % confidence interval (CI) and AIC for each model,
are reported in Table 3. For models 1 and 3, the AIC
was lower when weighted by sample size, and we focus
on these results below. For model 2, the AIC values were
very close and thus the sample size weighted model was
chosen for consistency. The observed versus fitted values
and the corresponding residuals for each model are pre-
sented in Additional file 4.
Predicting average CFB in VAS pain score at 6 weeks
CFB in VAS pain score at 2 weeks was significantly asso-
ciated with CFB in VAS pain score at 6 weeks (regres-
sion coefficient 0.9, 95 % CI 0.8–1.0); intercept −4.6,
95 % CI −6.9, −2.4). A scatterplot of observed data per
arm at both time points, along with predicted regression
lines N-weighted and precision-weighted, is presented in
Fig. 1.
Predicting average CFB in VAS pain score at 12 weeks
CFB in VAS pain score at 2 weeks was significantly asso-
ciated with CFB in VAS pain score at 12 weeks (regres-
sion coefficient 0.8, 95 % CI 0.7–0.8; intercept −8.3,
95 % CI −10.4, −6.2). Similarly, CFB in VAS pain score
at 6 weeks was found to be highly predictive and very close
to CFB in VAS pain score at 12 weeks (regression coeffi-
cient 0.9, 95 % CI 0.9–1.0; intercept −1.5, 95 % CI −3.1,
0.2). Scatterplots of observed CFB in VAS pain data per
arm at 2 and 12 weeks and 6 and 12 weeks, along with the
predicted regression lines, are presented in Figs. 2 and 3,
respectively.
Discussion
In this study, we assessed the association and predictive
ability of CFB in VAS pain score between the time
points of 2, 6 and 12 weeks in RCTs of OA and RA. The
analysis was based on data derived from a systematic lit-
erature review of published RCTs comparing diclofenac,
ibuprofen, naproxen, celecoxib or etoricoxib with each
other or with placebo [20]. That review provided a
unique opportunity to explore the relationship between
early and late pain responses in RCTs.
The results suggest that average CFB in VAS pain
scores at all time points are highly associated. CFB in
VAS pain score at 2 weeks was predictive of response at
both 6 and 12 weeks. CFB in VAS pain score at 6 weeks
is also predictive and almost identical to CFB in VAS
pain score at 12 weeks. This is in accordance with
individual patient-level responder analysis of etoricoxib,
celecoxib, naproxen and ibuprofen over 2–12 weeks,
where the proportion of patients achieving various levels
of response was consistent at 2, 4, 8 and 12 weeks [22].
Earlier, Bingham and colleagues demonstrated a
similar predictive effect of early response to NSAIDs in
predicting later response in a pooled analysis of two
identical 26-week studies testing etoricoxib, celecoxib
Table 1 Descriptive statistics for change from baseline in visual
analogue scale pain
VAS pain Mean Median Minimum Maximum
CFB at 2 weeks −21.0 −21.8 −35.5 −0.3
CFB at 6 weeks −23.5 −24.5 −46.9 −1.0
CFB at 12 weeks −21.0 −21.9 −42.9 1.8
Table 2 Sample size weighted Pearson correlation coefficients
(r values) for change from baseline in visual analogue scale pain
Time point 2 weeks 6 weeks 12 weeks
2 weeks 1
6 weeks 0.84 1
12 weeks 0.79 0.96 1
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and placebo in patients with OA of the hip and knee.
With active treatment, around 75 % of patients who
were responders at 2 weeks were also responders at
12 weeks [16]. This is also the case in fibromyalgia [17]
and acute pain in individual patient-level analyses [18].
In these examples, the converse is also true: lack of early
response indicates that later response is very unlikely.
The situation may be different for the anti-depressant
duloxetine in several chronic pain states [23].
The finding that early response is predictive of later re-
sponse is important in a number of ways. In clinical prac-
tice, for example, it can be used to consider ‘stopping rules’,
whereby the failure to achieve a certain level of pain relief
by 2 or 6 weeks with one NSAID would mean that the
therapy is reviewed, the dose is escalated or a switch is
made to another analgesic. Together with the knowledge
that analgesics provide good pain relief in only a portion of
patients [23], this can change the way guidance is
formulated. For example, an early opportunity to assess effi-
cacy and switch in the case of non-response might be built
into care pathways in the future. This opportunity may not
be available in current usual care, where patients may
discuss therapeutic responses many months after treat-
ments have been initiated. Early switching forms part of the
guidance for neuropathic pain in England and Wales.
These ideas can also inform appropriate treatment dur-
ation in designing a clinical trial (with consideration of
both tolerability and efficacy). For example, studies of effi-
cacy could be shorter, perhaps 6 instead of 12 weeks. But
studies of harm, which are typically longer and often larger,
might be considered unethical if they included a large pro-
portion of patients who were at risk but had no benefit;
studies of harm might have to have quite different designs,
perhaps based on cohorts of only those patients who actu-
ally benefit. However, the actual design can build in aspects
of this knowledge, either in pragmatic trials of switching
Table 3 Weighted regression models for change from baseline in visual analogue scale pain
Model Predictor Outcome N-weighted SE-weighted
Slope (95 % CI) Intercept (95 % CI) AIC Slope (95 % CI) Intercept (95 % CI) AIC
1 2 weeks 6 weeks 0.9 (0.8–1.0) −4.6 (−6.9, −2.4) 394 0.9 (0.8–1.0) −4.0 (−6.8, −1.1) 450
2 2 weeks 12 weeks 0.8 (0.7–0.8) −8.3 (−10.4, −6.2) 256 0.7 (0.7–0.8) −8.5 (−10.4, −6.5) 256
3 6 weeks 12 weeks 0.9 (0.9–1.0) −1.5 (−3.1, 0.2) 253 0.9 (0.9–1.0) −1.2 (−2.8, 0.3) 261
AIC Akaike information criterion, CI confidence interval, N sample size, SE standard error
Fig. 1 CFB in VAS pain 2-week data versus CFB in VAS pain 6-week data. A scatterplot of observed CFB data from RCT arms is displayed along
with predicted regression lines, N-weighted (red line) and precision-weighted (blue line). AIC Akaike information criterion; CFB change from
baseline, RCT randomised controlled trial, VAS visual analogue scale
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Fig. 2 CFB in VAS pain 2-week data versus CFB in VAS pain 12-week data. A scatterplot of observed CFB data from RCT arms is displayed along
with predicted regression lines, N-weighted (red line) and precision-weighted (blue line). AIC Akaike information criterion; CFB change from
baseline, RCT randomised controlled trial, VAS visual analogue scale
Fig. 3 CFB in VAS pain 6-week data versus CFB in VAS pain 12-week data. A scatterplot of observed CFB data from RCT arms is displayed along
with predicted regression lines, N-weighted (red line) and precision-weighted (blue line). AIC Akaike information criterion; CFB change from
baseline, RCT randomised controlled trial, VAS visual analogue scale
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therapy in the face of non-response, designs for which have
been proposed [23], or in the greater use of enriched enrol-
ment randomised withdrawal designs [24].
Limitations of this study should be borne in mind when
interpreting the results. The limitations related to avail-
ability of data and the potential for within-study bias and
publication bias have been extensively discussed elsewhere
[20]. Our analyses are directed to within-trial compari-
sons, where issues relating to quality and availability of
data or use of different imputation methods for missing
data are minimised. There is no reason to suspect any
differential effect of publication bias, as the results of the
original searches were cross-checked against the results of
the Coxib and traditional NSAID Trialists’ Collaboration
study [25]. Furthermore, the analyses presented herein are
based on aggregated data; thus, and while there is a theor-
etical risk of ecological fallacy (i.e., results not translatable
on the individual patient level), there is existing evidence
from individual patient-level analyses in OA that this is
not the case [16]. One final comment is that we have con-
centrated only on patient-reported pain; in few studies have
researchers reported markers of inflammation, and none
commented on links between inflammation and pain in the
timing of any changes on average or in individual patients.
The predictive ability of the models was assessed by
examining the discrepancies between observed and
predicted values and the standardised residuals. In
Additional file 1, it can be seen that all models
perform well.
Conclusions
For patients with OA and RA, early analgesic response
measured by VAS for pain beyond 2 weeks of treatment
with a particular NSAID is likely to be predictive of
response at 12 weeks. Failure to achieve desired pain relief
after 2 weeks of treatment should trigger reassessment of
dosage and/or choice of analgesic.
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